Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro

Synapse

Volumn 63, Issue 11, 2009, Pages 998-1009

  McCormick, Patrick N ^a,b   Kapur, Shitij ^b,c   Reckless, Greg ^b   Wilson, Alan A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

11C (+) PHNO; 3H raclopride; Agonist; Brain biodistribution; DA D2 receptor; Dual radiotracer; High affinity state; Positron emission tomography (PET); Rat; Sensitization

Indexed keywords

ALCOHOL; DOPAMINE 2 RECEPTOR; NAXAGOLIDE; RACLOPRIDE; TRACER; CARBON; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; EX VIVO STUDY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; METABOLISM; POSITRON EMISSION TOMOGRAPHY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 70349300679     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20671     Document Type: Article

References (91)

1. 3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology 18:305-316.
2. 2 receptor. Life Sci 37:379-386.
3. 2 high receptors. Eur Neuropsychopharmacol 18:551-556.
4. Castner SA, Goldman-Rakic PS. 1999. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20:10-28.
5. Castner SA, Goldman-Rakic PS. 2003. Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry 54:105-110.
6. 123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology 22:4-13.
7. 2 dopamine receptors in the rat ventral striatum during amphetamine sensitization. Life Sci 64:343-354.
8. Costall B, Naylor RJ, Pycock C. 1976. Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway. Eur J Pharmacol 35:276-283.
9. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002a. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 965:440-450. (Pubitemid 34721991)
10. Cumming P, Wong DF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002b. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22:596-604.
11. De Keyser J, Walraevens H, De Backer JP, Ebinger G, Vauquelin G. 1989. D2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals. Brain Res 484:36-42. (Pubitemid 19100063)
12. De Lean A, Stadel JM, Lefkowitz RJ. 1980. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255:7108-7117. (Pubitemid 11232874)
13. Dykstra D, Hazelhoff B, Mulder TBA, De Vries JB, Wynberg H, Horn AS. 1985. Synthesis and pharmacological activity of the hexahydro-4H-naphth[1,2b][1, 4]-olazines: a new series of potent dopamine receptor agonists. Eur J Med Chem Chim Ther 20:247-250.
14. 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 36:269-273.
15. 11C]MNPA in cynomolgus monkey. Nucl Med Biol 32:353-360.
16. 2/3 receptor occupancy of apomorphine in the non-human primate brain does not support existence of two affinity states in vivo. Neuroimage 41(Suppl 2):T19.
17. 11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse 60:172-183.
18. 2long dopamine receptors: ligand binding and functional assays. Br J Pharmacol 124:978-984.
19. 2short dopamine receptors determined in ligand binding and functional assays. J Neurochem 69:2589-2598.
20. 2 receptor with G alpha i1. G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
21. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117:690-697. (Pubitemid 15237891)
22. 2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31:154-162.
23. 11C]raclopride in rats. Synapse 52:89-99.
24. 2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103.
25. 11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27:857-871.
26. 11C]raclopride in healthy humans. Hum Brain Mapp 29:400-410.
27. 2 antagonist. Psychopharmacol Ser 7:123-130.
28. 2-dopamine receptor density during chronic ethanol intake. Alcohol 9:133-137.
29. 2 receptor characteristics in rat brain. Neurosci Lett 108:289-294.
30. 2 receptors. Nucl Med Biol 27:533-539.
31. 11C-propyl-norapomorphine in vivo binding in nonhuman primates. J Nucl Med 45:338-346.
32. Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T, Okano H, Nariai T, Ohno K, Obayashi S, Higuchi M, Suhara T. 2005. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 1064:136-145. (Pubitemid 41774653)
33. 18F]fluoro-L-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats. Neurosci Lett 389:30-34.
34. Itzhak Y, Martin JL. 1999. Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain Res 818:204-211. (Pubitemid 29229933)
35. Jones JH, Anderson PS, Baldwin JJ, Clineschmidt BV, McClure DE, Lundell GF, Randall WC, Martin GE, Williams M, Hirshfield JM, Smith G, Lumma PK. 1984. Synthesis of 4-substituted 2H-naphth[ 1,2-b]-1,4-oxazines, a new class of dopamine agonists. J Med Chem 27:1607-1613. (Pubitemid 15177901)
36. 3 agonist 7-OH-DPAT (7-hydroxy- dipropylaminotetralin) and antipsychotic drugs measured ex vivo by quantitative autoradiography. Can J Physiol Pharmacol 78:7-11.
37. 3H] spiroperidol binding in rat brain after repeated methamphetamine administration. Eur J Pharmacol 72:101-105.
38. 2 dopamine receptor expression in the rat brain. Mol Cells 7:682-687.
39. Klug JM, Norman AB. 1993. Long-term sensitization of apomorphine- induced rotation behavior in rats with dopamine deafferentation or excitotoxin lesions of the striatum. Pharmacol Biochem Behav 46:397-403. (Pubitemid 23307071)
40. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
41. 2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 41:473-481.
42. 2 synergism are unrelated to changes in striatal receptor density. Synapse 12:14-26.
43. 3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5:145-153.
44. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451. (Pubitemid 30164887)
45. Lessov CN, Phillips TJ. 1998. Duration of sensitization to the locomotor stimulant effects of ethanol in mice. Psychopharmacology (Berl) 135:374-382.
46. 3 dopamine receptors in the brains of several mammalian species. Brain Res 800:269-274.
47. 3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159.
48. Manley SJ, Little HJ. 1997. Enhancement of amphetamine- and cocaine- induced locomotor activity after chronic ethanol administration. J Pharmacol Exp Ther 281:1330-1339. (Pubitemid 27258393)
49. Martin GE, Williams M, Pettibone DJ, Yarbrough GG, Clineschmidt BV, Jones JH. 1984. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol Exp Ther 230:569-576. (Pubitemid 14040373)
50. Martin GE, Williams M, Pettibone DJ, Zrada MM, Lotti VJ, Taylor DA, Jones JH. 1985. Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo. J Pharmacol Exp Ther 233:395-401. (Pubitemid 15122038)
51. 11C]-(+)-PHNO. Neuroimage 31:T12-T43.
52. 2 agonists and antagonists ex vivo. Nucl Med Biol 35:11-17.
53. Mileson BE, Lewis MH, Mailman RB. 1991. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res 561:1-10.
54. 11C]WC-10 in non-human primates. J Nucl Med 49 (Suppl 1):286P.
55. 11C]-raclopride. Synapse 52:188-208.
56. 11C]raclopride in baboons. J Pharmacol Exp Ther 315:80-90.
57. 3 receptor preferring agonist in vivo. Synapse 60:485-495.
58. 11C]NPA) in an anesthetized nonhuman primate. Synapse 61:106-109.
59. Neve KA, Marshall JF. 1984. The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive in the rat. Neurosci Lett 46:77-83.
60. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berl) 90:287-294.
61. Patrick SL, Thompson TL, Walker JM, Patrick RL. 1991. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus. Brain Res 538:343-346.
62. 2short dopamine receptor. J Neurochem 82:1106-1117.
63. 2 components of ex vivo regional (+)- PHNO brain binding in wild-type and knock-out mice. J Nucl Med 48 (Suppl 2):113P.
64. 3H-spiroperidol binding in mice after chronic administration of high doses of apomorphine, N-n-propylnorapomorphine and dextroamphetamine. Psychopharmacology (Berl) 77:146-149.
65. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198.
66. Russo KE, Hall W, Chi OZ, Sinha AK, Weiss HR. 1991. Effect of amphetamine on cerebral blood flow and capillary perfusion. Brain Res 542:43-48.
67. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. 2007. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986. (Pubitemid 46438984)
68. Sams-Dodd F. 1998. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19:18-25. (Pubitemid 28255210)
69. Schwarting RK, Huston JP. 1996a. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331.
70. Schwarting RK, Huston JP. 1996b. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215-266.
71. High receptors on intact cells. Synapse 62:314-318.
72. Seeman P, Ulpian C, Larsen RD, Anderson PS. 1993. Dopamine receptors labelled by PHNO. Synapse 14:254-262.
73. 2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46:235-239.
74. 2high receptors, reversed by general anesthesia: relation to relapse? Synapse 52:77-83.
75. high receptors. Synapse 58:122-128.
76. High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102:3513-3518.
77. 3H](+)PHNO. Synapse 61:263-267.
78. 11C]raclopride. Synapse 59:260-269.
79. 11C]MNPA: A dopamine agonist radioligand. Synapse 62:700-709.
80. 11C]MNPA. Synapse 62:756-763.
81. Sibley DR, De Lean A, Creese I. 1982a. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257:6351-6361. (Pubitemid 12029548)
82. 3H]antagonist dopamine receptor binding. Experientia 38:1224-1225.
83. Sibley DR, Mahan LC, Creese I. 1983. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol 23:295-302.
84. 2-like receptors. Clin Exp Pharmacol Physiol Suppl 26:S3-S9.
85. Tenn CC, Fletcher PJ, Kapur S. 2003. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64:103-114. (Pubitemid 37412332)
86. 11C]MNPA and its response to methamphetamine in the monkey brain. Neuroimage 41(Suppl 2):T40.
87. 2-antagonist raclopride in the nucleus accumbens of the rat on spontaneous and D-amphetamine-induced activity. Psychopharmacology (Berl) 95:447-451.
88. 11C]-(+)-PHNO. Biol Psychiatry 59:389-394.
89. 11C]-(+)- PHNO positron emission tomography study. Neuropsychopharmacology 33:279-289.
90. 18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol 23:141-146.
91. 2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160.